Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Waxman Asks FDA To Explain How Its Regulatory Priorities Aid Public Health

This article was originally published in The Gray Sheet

Executive Summary

Rep. Henry Waxman, D-Calif., is challenging FDA's priorities for writing rules and guidances, saying the agency appears to be more interested in loosening marketing restrictions and reducing product liability for drug and device makers than in protecting public health

You may also be interested in...



Extra Caution Needed In Uncertain Period For Off-Label Info Distribution

Until FDA finalizes guidance on what practices are acceptable in distributing journal articles that describe off-label product indications, companies should watch their step in avoiding investigations that could lead to fines, criminal prosecution or exclusion from federal reimbursement programs, attorneys say

FDA Finalizes Labeling Revision Rule; Similar To Controversial Proposal

FDA is sticking with its plan to define when approved medical product labels can be changed without prior authorization from the agency

In Victory For Device Industry, Supreme Court Favors PMA Pre-emption

In a ruling that is expected to shave the volume of lawsuits against device manufacturers, the Supreme Court held that FDA premarket approval should preclude patients from suing companies for personal injury in most cases

Related Content

UsernamePublicRestriction

Register

MT026603

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel